Clinical ResultsMultiple doses of INB-200 showed mPFS of 16.1 months, beating historical benchmarks of 6.2 months and 10.3 months in GBM patients with unmethylated or methylated MGMT promoter, respectively.
Preclinical DataIN8bio presented promising preclinical data with their CD19 targeting γδ TCE (INB-619) showing deep B cell depletion in blood samples from lupus patients.
Strategic PartnershipsManagement is exploring partnership and collaboration options to further develop the program, indicating strategic growth opportunities.